Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
复制标题
DOI：
10.1038/s41591-021-01387-6
复制
发表时间：
2021-08
期刊：
影响因子：
82.9
通讯作者：
Turajlic S
中科院分区：
文献类型：
--
作者：
Au L;Fendler A;Shepherd STC;Rzeniewicz K;Cerrone M;Byrne F;Carlyle E;Edmonds K;Del Rosario L;Shon J;Haynes WA;Ward B;Shum B;Gordon W;Gerard CL;Xie W;Joharatnam-Hogan N;Young K;Pickering L;Furness AJS;Larkin J;Harvey R;Kassiotis G;Gandhi S;Crick COVID-19 Consortium;Swanton C;Fribbens C;Wilkinson KA;Wilkinson RJ;Lau DK;Banerjee S;Starling N;Chau I;CAPTURE Consortium;Turajlic S
癌症患者目前在全球冠状病毒疾病2019年(新冠肺炎)疫苗接种计划中被列为优先事项，其中包括接种信使核糖核酸疫苗。细胞因子释放综合征(CRS)在基因疫苗中尚未见报道，是一种极为罕见的免疫检查点抑制剂的免疫相关不良事件。我们报告了一例长期接受抗PD-1单药治疗的结直肠癌患者在接种BTN162b2(托津那美兰)-辉瑞-BioNTech mRNA新冠肺炎疫苗-5天后发生CRS的病例。炎症标志物升高、血小板减少、细胞因子水平升高(干扰素-γ/IL-2R/IL-18/IL-16/IL-10)和类固醇反应性是CRS的证据。在这个病例中，接种疫苗和诊断CRS的时间关系密切，这表明CRS是疫苗相关的不良事件；抗PD1阻断是一个潜在的因素。总体而言，在癌症患者中需要进一步的前瞻性药效数据，但在这一人群中，益处-风险概况仍然强烈支持新冠肺炎疫苗接种。在接受抗PD-1阻断的患者中出现一例罕见的细胞因子释放综合征，可能与接种BNT162b2疫苗有关，这支持了对新冠肺炎疫苗接种后癌症患者的前瞻性监测。
Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)—the Pfizer-BioNTech mRNA COVID-19 vaccine—in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit–risk profile remains strongly in favor of COVID-19 vaccination in this population. A rare case of cytokine release syndrome in a patient on anti-PD-1 blockade that was likely related to BNT162b2 vaccination supports prospective monitoring of patients with cancer after COVID-19 vaccine administration.
登录
查看更多内容
DOI：
10.1016/s1470-2045(21)00155-8
发表时间：
2021-05
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Waissengrin B;Agbarya A;Safadi E;Padova H;Wolf I
通讯作者：
Wolf I
DOI：
10.1056/nejmoa2104840
发表时间：
2021-06-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者：
Eichinger S
DOI：
10.1038/nrclinonc.2017.148
发表时间：
2018-01
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Neelapu SS;Tummala S;Kebriaei P;Wierda W;Gutierrez C;Locke FL;Komanduri KV;Lin Y;Jain N;Daver N;Westin J;Gulbis AM;Loghin ME;de Groot JF;Adkins S;Davis SE;Rezvani K;Hwu P;Shpall EJ
通讯作者：
Shpall EJ
血清表位曲目分析可早期检测莱姆病，并以可扩展的多重形式提高灵敏度。
影响因子：
9.4
作者：
Reifert J;Kamath K;Bozekowski J;Lis E;Horn EJ;Granger D;Theel ES;Shon J;Sawyer JR;Daugherty PS
通讯作者：
Daugherty PS
影响因子：
28.2
作者：
Ribas A;Sengupta R;Locke T;Zaidi SK;Campbell KM;Carethers JM;Jaffee EM;Wherry EJ;Soria JC;D'Souza G;AACR COVID-19 and Cancer Task Force
通讯作者：
AACR COVID-19 and Cancer Task Force